{{Rsnum
|rsid=4723619
|Gene=ELMO1
|Chromosome=7
|position=37226747
|Orientation=plus
|GMAF=0.1006
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ELMO1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 7.1 | 92.9
| HCB | 3.6 | 35.8 | 60.6
| JPT | 2.7 | 31.0 | 66.4
| YRI | 1.4 | 12.2 | 86.4
| ASW | 0.0 | 15.8 | 84.2
| CHB | 3.6 | 35.8 | 60.6
| CHD | 4.6 | 27.5 | 67.9
| GIH | 1.0 | 13.9 | 85.1
| LWK | 0.9 | 18.2 | 80.9
| MEX | 3.4 | 22.4 | 74.1
| MKK | 1.3 | 14.1 | 84.6
| TSI | 0.0 | 3.9 | 96.1
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=19176441
|Trait=Treatment response for acute lymphoblastic leukemia
|Title=Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia
|RiskAllele=C
|Pval=0.000003
|OR=3.01
|ORtxt=[1.50-6.03]
|OA=1
}}

{{PharmGKB
|RSID=rs4723619
|Name_s=
|Gene_s=ELMO1
|Feature=
|Evidence=PubMed ID:19176441; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. (Initial Sample Size: 487 children; Replication Sample Size: NR); (Region: 7p14.2; Reported Gene(s): ELMO1; Risk Allele: rs4723619-C); (p-value= 0.000003).This variant is associated with Treatment response for acute lymphoblastic leukemia.
|Drugs=
|Drug Classes=
|Diseases=Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164740032
}}

{{PharmGKB
|RSID=rs4723619
|Name_s=
|Gene_s=ELMO1
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.07, combined P value= 3.05E-06. It is also associated with greater methotrexate and etoposide clearance.
|Drugs=etoposide; methotrexate
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470154
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4723619
|overall_frequency_n=13
|overall_frequency_d=128
|overall_frequency=0.101562
|n_genomes=10
|n_genomes_annotated=0
|n_haplomes=11
|n_articles=1
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
|n_web_uneval=7
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}